Auris Medical — Treatment of Tinnitus Through Modulation of Chloride Co-Transporter NKCC1

Discussion in 'Research News' started by ChrisBoyMonkey, Jan 29, 2020.

    1. ChrisBoyMonkey

      ChrisBoyMonkey Member Podcast Patron

      Location:
      US
      Tinnitus Since:
      2019
      Cause of Tinnitus:
      Noise
      • Received “Intention to Grant” notice from European Patent Office
      • Application covers invention of oral treatment for tinnitus
      Hamilton, Bermuda, January 10, 2020 – Auris Medical Holding Ltd. (NASDAQ: EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in neurotology and central nervous system disorders, today announced that the European Patent Office (EPO) has issued a notice of “Intention to Grant” for its patent application entitled “Treatment of Tinnitus Through Modulation of Chloride Co-Transporter NKCC1 in the Auditory System” (European Patent Application 11 894 529.3).

      The allowed claims cover compounds modulating the sodium potassium chloride co-transporter 1 (NKCC1) for use in the oral treatment or prevention of tinnitus. As demonstrated in an animal model of acute noise trauma, administration of an NKCC1 inhibitor resulted in a significant reduction of a biomarker for the presence of tinnitus (p<0.02). Inhibition of NKCC1 reduces trauma-induced excessive intracellular chloride ion levels in inner hair cells and the resulting neural hyperexcitability in the auditory system, which underlies the perception of tinnitus.

      The communication from the EPO concludes substantive examination of the patent application, which is now expected to issue as a patent once the issue fees are paid and the patent office concludes its respective administrative procedures. A corresponding patent application is currently pending before the US Patent and Trademark Office (USPTO) and was already granted in Japan.

      “We are very pleased with this new addition to our patent estate in tinnitus, which remains an area of great unmet medical need“, commented Thomas Meyer, Auris Medical’s founder, Chairman and CEO. “NKCC1 represents a new and promising target for tinnitus therapy, particularly because it may allow for oral treatment and thus complement Keyzilen®, our investigational tinnitus drug for intratympanic administration. We intend to develop a proprietary NKCC1 inhibitor through our new subsidiary, Zilentin Ltd., which we recently established in order to bundle our activities and assets within the therapeutic areas of tinnitus and hearing loss.”

      https://www.globenewswire.com/news-...llowance-for-European-Patent-Application.html
       
      • Like Like x 2
      • Informative Informative x 1
    2. TibuJenkins

      TibuJenkins Member Podcast Patron

      Tinnitus Since:
      12/2018
      Cause of Tinnitus:
      Ear wax removal with suction by ENT
      This is extremely interesting. Is this in the same vein as the KCNQ potassium channels investigated by Dr. Thanos?
       
      • Good Question Good Question x 2
    3. Benoves

      Benoves Member Benefactor

      Tinnitus Since:
      26-9-2017
      Cause of Tinnitus:
      Unknow possibly noise trauma
      Is this only for acute tinnitus or also for chronic?
       
      • Good Question Good Question x 5
    4. El BUZZ
      Buzzed

      El BUZZ Member

      Tinnitus Since:
      2015
      Cause of Tinnitus:
      Loud music consumption plus acoustic trauma.
      But Keyzilen is nothing but AM-101 which just failed in its phase 3 clinical trial... Am I wrong?
       
      • Good Question Good Question x 1
    5. AUTHOR
      AUTHOR
      ChrisBoyMonkey

      ChrisBoyMonkey Member Podcast Patron

      Location:
      US
      Tinnitus Since:
      2019
      Cause of Tinnitus:
      Noise
      It's not Keyzilen. It's more akin to what Dr. Tzounopoulos is working on, potassium ion channels.
       
      • Informative Informative x 1
    6. mrbrightside614

      mrbrightside614 Member Podcast Patron Benefactor Advocate

      Location:
      NE Ohio, USA
      Tinnitus Since:
      July 2019
      Cause of Tinnitus:
      Acoustic trauma
      Never seen a biomarker for tinnitus... this is definitely a completely unique approach, for which I am glad because there are at least 3 known companies working on Thanos’s KV7 channel targets, with two of them indicating applications for tinnitus.
       
      • Informative Informative x 1
    7. Mentos

      Mentos Member Benefactor

      Location:
      Cracow, Poland
      Tinnitus Since:
      03/2015
      Cause of Tinnitus:
      Noise induced, loud rock concert
      Anyone have any idea when the clinical trials should start?
       
      • Good Question Good Question x 3
    8. Frédéric

      Frédéric Member Podcast Patron Benefactor Advocate

      Location:
      Marseille, France
      Tinnitus Since:
      11/19/2012
      Cause of Tinnitus:
      acoustic trauma
      • Like Like x 1
      • Good Question Good Question x 1
    9. FGG
      No Mood

      FGG Member Podcast Patron Benefactor Hall of Fame Advocate

      Tinnitus Since:
      01/2019
      Cause of Tinnitus:
      Multi-factorial
      • Agree Agree x 1
    10. Frédéric

      Frédéric Member Podcast Patron Benefactor Advocate

      Location:
      Marseille, France
      Tinnitus Since:
      11/19/2012
      Cause of Tinnitus:
      acoustic trauma
      Yes I checked the Net, and it seems their website does not yet exist.
       
      • Agree Agree x 1
    11. Paulmanlike

      Paulmanlike Member Podcast Patron Benefactor Hall of Fame

      Tinnitus Since:
      2008
      Cause of Tinnitus:
      Noise
      Auris Medical gained almost 20% on its stock price today. I have no idea why, nor researched it, but worth looking into.
       
      • Good Question Good Question x 1
    12. Greg Sacramento

      Greg Sacramento Member Benefactor Hall of Fame

      Tinnitus Since:
      April 2011
      Cause of Tinnitus:
      syringing and now somatic T dental work
      I saw a large block share buy backed by a spread option at the open of regular hours. It dipped a little from a 20% rise and then smaller block shares that were also supported by option spreads were made. Only 6% of holdings is that of institutions and none appear to have spread options - eagle spreads, so probably an investor group wanted to close the money gap on open interest.

      The only news that I could find at the open was that analysis of top-line data - their Phase 1b trial -
      that is evaluating AM-201 in healthy volunteers will be released soon.

      I think that the gap was closed too tight - no room for investment error, unless the analysis of news is quite outstanding.
       
      • Informative Informative x 2
    13. Croaker
      Haunting

      Croaker Member

      Tinnitus Since:
      01/2019
      Cause of Tinnitus:
      Unknown
      This is interesting. If this works along the same lines as Thanos’ Trobalt reformulation, it means that we may see phase 1 results within a year or so! I think this strategy looks very promising (are they saying they found tinnitus biomarkers?!) but I thought it would be years before we saw any quality data one way or another. (Data about any drug trying this potassium ion channel blocking to clarify.)

      That being said, they haven’t updated their pipeline so AM 102 still says they’re searching for a compound... hopefully that changes soon.
       

Share This Page

Loading...